QIAGEN GMBH
Desconocido
ColoMARK: Identification and development of novel colorectal cancer biomarkers via state of the art liquid bio...
QIAGEN GMBH
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2021-DN-01
The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinfor...
2022-07-06 - 2026-10-31 | Financiado
2022-07-06 - 2026-10-31 | Financiado
EASI-Genomics: European Advanced infraStructure for Innovative Genomics
QIAGEN GMBH
participó en un
H2020:
H2020-INFRAIA-2018-2020
Next-generation sequencing (NGS) has taken modern research by storm and consequently is one of the most important tools of modern biological...
2018-11-20 - 2023-07-31 | Financiado
2018-11-20 - 2023-07-31 | Financiado
EU-STANDS4PM: A European standardization framework for data integration and data driven in silico models for perso...
QIAGEN GMBH
participó en un
H2020:
H2020-SC1-BHC-2018-2020
The capacity to generate data in Life Sciences and health research with modern omics and imaging technologies has increased many orders of m...
2018-11-13 - 2022-12-31 | Financiado
2018-11-13 - 2022-12-31 | Financiado
MASTER: Microbiome Applications for Sustainable food systems through Technologies and EnteRprise
QIAGEN GMBH
participó en un
H2020:
H2020-SFS-2018-2020
Although microorganisms dominate almost every ecological niche in our planet, it has only been during the past 10-15 years that we have begu...
2018-10-10 - 2023-07-01 | Financiado
2018-10-10 - 2023-07-01 | Financiado
SPIDIA4P: SPIDIA for Personalized Medicine Standardisation of generic Pre analytical procedures for In vitro...
QIAGEN GMBH
tramitó un
H2020:
H2020-SC1-2016-2017
Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited...
2016-11-30 - 2021-06-30 | Financiado
2016-11-30 - 2021-06-30 | Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate...
QIAGEN GMBH
participó en un
FP6:
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
2015-01-01 - 2019-12-31 | Financiado
2015-01-01 - 2019-12-31 | Financiado
METABOLOMICSSTANDARD: Metabolomics defining the standards for sample preparation of small molecules
QIAGEN GMBH
tramitó un
FP7:
The general aim of metabolomics is to identify measure and interpret the complex time-related concentration, flux and activity of the metabo...
Financiado
Financiado
SPIDIA: Standardisation and improvement of generic pre analytical tools and procedures for in vitro diagnost...
QIAGEN GMBH
tramitó un
FP7:
In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: (a) the lack of guidelines in collect...
Financiado
Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate...
QIAGEN GMBH
participó en un
FP7:
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
Financiado
Financiado
NANOCARD: Nanopatterned scaffolds for active myocardial implants
QIAGEN GMBH
participó en un
FP7:
Cell therapy and tissue engineering are emerging as novel therapeutic paradigms for myocardial repair. The rationale behind the cell replace...
Financiado
Financiado
* No se disponen de datos de la empresa actual.